Assuntos
Cirurgia Bariátrica , Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Derivação Gástrica , Obesidade Mórbida , Humanos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/cirurgia , Doenças Cardiovasculares/cirurgia , Obesidade/complicações , Obesidade/cirurgia , Duodeno/cirurgia , Fatores de Risco , Cirurgia Bariátrica/efeitos adversos , Resultado do Tratamento , Obesidade Mórbida/complicações , Obesidade Mórbida/cirurgia , Derivação Gástrica/efeitos adversosRESUMO
BACKGROUND: Atopic dermatitis (AD) is a chronic skin disease characterized by dry skin, severe itching, inflammation and impaired quality of life. Moisturizing is an integral part of treatment for AD, but its potential for prevention of AD is unclear. OBJECTIVE: To evaluate whether the early use of emollients in infancy can prevent later development of AD. METHODS: We searched Medline, Embase, Web of Science, PubMed, Cochrane Library and other databases to collect randomized controlled trials on early use of emollients in infants for a meta-analysis. RESULTS: Nine articles were included. The OR value for incidence rate was 0.7 (95% CI: 0.48-1.01). No significant publication bias was found by Egger's test. The sensitivity analysis indicated that the final conclusion was reliable. CONCLUSIONS: We found that the difference in incidence rate of AD between the experimental and control groups was not statistically significant. However, due to different methods of using emollients, different follow-up times and different sample sizes included in this meta-analysis, a definitive conclusion could not be reached in this study. In the future, it is still necessary to carry out randomized controlled, multicenter, large-sample trials with an excellent study design and high methodological quality on early application of emollients in high-risk infants to prevent AD.
Assuntos
Dermatite Atópica , Emolientes , Dermatite Atópica/epidemiologia , Emolientes/uso terapêutico , Humanos , Incidência , Lactente , Qualidade de VidaRESUMO
BACKGROUND: The endoscopic duodenal-jejunal bypass liner (DJBL) represents a novel temporary endoscopic approach for treatment of obesity-associated type 2 diabetes. Recent results from the German DJBL registry confirmed substantial positive metabolic effects of the DJBL in type 2 diabetes. However, the last Food and Drug Administration trial was stopped due to a high occurrence of hepatic abscesses (3.5%). OBJECTIVES: Here, we analyzed time courses of development of co-morbidities, nutritive changes, and occurrence of adverse events during the 1-year treatment phase with the DJBL in the German DJBL registry. METHODS: Sixty-six patients from the registry were analyzed for efficacy, safety, and nutritional status. Patient data sets were analyzed at implantation, 3 and 6 months after implantation, and at explantation visits. RESULTS: Weight, body mass index, glycated hemoglobin, and low-density lipoprotein cholesterol primarily declined during the first 3 months after implantation, whereas systolic and diastolic blood pressure were predominantly reduced during the second half of the treatment phase. Severe DJBL-associated side effects were mainly documented at the explantation visit (intestinal obstruction [1.7%], dislocation [1.7%], and liver abscess [1.7%]). Measurements of serum concentrations of ferritin, albumin, vitamin B12, folic acid, 25-hydroxyvitamin D3 (25 OH-Vit-D3), and calcium provided suggestive evidence of a possible decrease of nutritional absorption of vitamins and trace elements by the DJBL. CONCLUSIONS: The DJBL demonstrates high efficacy with substantial improvement of all parameters of the metabolic syndrome and the potential for reduction of comedications in overweight patients with type 2 diabetes. These registry results are important to optimize recommendations for adaptation of concomitant medication, surveillance of adverse events, nutritional status and supplementation, and adaptation of the implantation period of the DJBL.
Assuntos
Cirurgia Bariátrica/métodos , Diabetes Mellitus Tipo 2/cirurgia , Duodeno/cirurgia , Jejuno/cirurgia , Estado Nutricional , Dor Abdominal/etiologia , Cirurgia Bariátrica/efeitos adversos , Cirurgia Bariátrica/instrumentação , Pressão Sanguínea/fisiologia , Índice de Massa Corporal , LDL-Colesterol/metabolismo , Diabetes Mellitus Tipo 2/complicações , Endoscopia Gastrointestinal/métodos , Feminino , Hemoglobinas Glicadas/metabolismo , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/complicações , Obesidade Mórbida/cirurgia , Complicações Pós-Operatórias/etiologia , Próteses e Implantes , Sistema de Registros , Resultado do TratamentoRESUMO
BACKGROUND: A novel-approach for treatment of obesity and diabetes mellitus type 2 (T2DM) is represented by the endoscopic duodenal-jejunal bypass liner (DJBL). Recent data from the German DJBL registry provide evidence for substantial efficacy of the DJBL during the implantation period in obese patients with T2DM. However, little is known about the trends of glycemic control, BMI, and comorbidities after explantation of the DJBL, which have been investigated in the registry in this report. METHODS: Patients were selected from the registry if they had a dataset at implantation, explantation, and at least one time point after explantation of the DJBL (n = 77). We also investigated a subgroup of patients with available data at least 1 year (-2 weeks) after explantation of the DJBL (n = 32). RESULTS: For a mean BMI at implantation and a mean follow-up period, an increase of BMI of 2.1 kg/m2 (CI 0.8-3.2; p = 0.013) had to be expected (for HbA1c 0.3% (CI - 0.0-0.7; p = n.s.), respectively). In the subgroup analysis, HbA1c and BMI increased after explantation of the DJBL but stayed significantly below baseline levels. Meanwhile, the mean number of antidiabetic drugs slightly increased. There was deterioration seen for blood pressure and LDL cholesterol over the postexplantation period to approximately baseline levels (or higher). CONCLUSION: With this data, we show that improvement of HbA1c and BMI can be partly maintained over a time of nearly 1-year postexplantation of the DJBL. However, for HbA1c, this may be biased by intensified medical treatment and effects deteriorated with time after explantation. These results suggest that implantation of the DJBL needs to be integrated in a long-term weight management program as most of other interventions in obese patients with T2DM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02731859.
Assuntos
Cirurgia Bariátrica/instrumentação , Glicemia/metabolismo , Índice de Massa Corporal , Trajetória do Peso do Corpo , Remoção de Dispositivo , Obesidade Mórbida , Adulto , Cirurgia Bariátrica/métodos , Comorbidade , Remoção de Dispositivo/efeitos adversos , Remoção de Dispositivo/métodos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/epidemiologia , Diabetes Mellitus Tipo 2/cirurgia , Duodeno/cirurgia , Feminino , Seguimentos , Alemanha/epidemiologia , Hemoglobinas Glicadas/metabolismo , Humanos , Jejuno/cirurgia , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/complicações , Obesidade Mórbida/epidemiologia , Obesidade Mórbida/cirurgia , Período Pós-Operatório , Próteses e Implantes , Sistema de Registros , Resultado do Tratamento , Redução de Peso/fisiologiaRESUMO
AIMS: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device mimicking surgical duodenal-jejunal bypass, and is indicated for the treatment of obesity-associated type 2 diabetes mellitus. This analysis was conducted to evaluate the efficacy and safety of the DJBL in comparison to lifestyle changes and antidiabetic drugs. MATERIALS AND METHODS: To determine the efficacy and long-term safety of the DJBL, data concerning 235 obese patients with type 2 diabetes mellitus from the German DJBL registry were analysed. For comparison with standard treatment, propensity-score-matching with patients from the German DPV registry, including the matching parameters sex, age, diabetes duration, baseline BMI and baseline HbA1c, was applied. The final matched cohort consisted of 111 patients in the DJBL group and 222 matched control DPV patients. RESULTS: Mean treatment time with the DJBL was 47.5 ± 12.2 weeks, mean BMI reduction was 5.0 kg/m2 (P < .001) and mean HbA1c reduction was 1.3% (11.9 mmol/mol) (P < .001). Reduction of antidiabetic medications and improvements in other metabolic and cardiovascular risk parameters was observed. In comparison to the matched control group, mean reductions in HbA1c (-1.37% vs -0.51% [12.6 vs 3.2 mmol/mol]; P < .0001) and BMI (-3.02 kg/m2 vs -0.39 kg/m2 ; P < .0001) were significantly higher. Total cholesterol, LDL cholesterol and blood pressure were also significantly better. CONCLUSION: This study provides the largest, so far, hypothesis-generating evidence for a putative positive risk/benefit ratio for treatment of obese patients with type 2 diabetes mellitus with the DJBL as an alternative treatment option for this patient population.